Lipid-lowering treatment in the improvement of outcomes in patients with atherosclerotic cardiovascular disease and diabetes mellitus: the role of PCSK9 inhibitors

PCSK9 inhibitors, diabetes mellitus, atherosclerotic cardiovascular diseases, low-density lipoprotein cholesterol

1. Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal. 2016;37:2999-3058. doi:10.1093/eurheartj/ehw272.

2. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European heart journal. 2016;37,29:2315-81. doi:10.1093/eurheartj/ehw106.

3. Rydén L, Grant PJ, Anker SD, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal. 2013;34:3035-87. doi:10.1093/eurheartj/eht108.

4. Jellinger PS, Handelsman Y, Rosenblit PD, et al. American association of clinical endocrinologists and American college of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocrine Practice. 2017;23,s2:187. doi:10.4158/EP171764.APPGL.

5. Ezhov MV, Sergienko IV, Aronov DM, et al. Diagnostics and correction of lipid metabolism disorders in order to prevent and treat atherosclerosis. Russian recommendations VI revision. Ateroskleroz i Dislipidemii. 2017;3:5-22. (In Russ.)

6. Dedov II, Shestakova MV, Mayorov AYu. Standardsof specialized diabetes care. 8th Edition. Diabetes mellitus. 2017;1S. (In Russ.) doi:10.14341/DM20171S8.

7. Sokolov AA, Alexandrova OYu, Kashtalap VV, et al. Guidelines on the medical care organization to the patients with hereditary atherogenic lipid disorders in the Regions of Russia (Joint project of the national society for the research on atherosclerosis and non-profit partnership The national council of experts on rare diseases). The Bulletin of Contemporary Clinical Medicine. 2017;10(1):83-8. (In Russ.) doi:10.20969/VSKM.2017.10(1).

8. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. New England Journal of Medicine. 2017;376(18):1713-22. doi:10.1056/NEJMoa1615664.

9. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome N Engl J Med. 2018 Nov 7. doi:10.1056/NEJMoa1801174. [Epub ahead of print].

10. Sabatine MS, Leiter LA, Wiviott SD, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. The Lancet Diabetes & Endocrinology. 2017;5(12):941-50. doi:10.1016/S2213-8587(17)30313-3.

11. Ray KK, Colhoun H, Szarek M, et al. Alirocumab and Cardiovascular Outcomes in Patients with Acute Coronary Syndrome (ACS) and Diabetes — Prespecified Analyses of ODYSSEY OUTCOMES. Diabetes. 2018 Jul;67(Supplement 1). doi:10.2337/db18-6-LB.

12. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine. 2015;372(25):2387-97. doi:10.1056/NEJMoa1410489.

13. Annemans L, Packard CJ, Briggs A, et al. ‘Highest risk–highest benefit’ strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies. European Heart Journal. 2018 July 14;39(27):2546-50. doi:10.1093/eurheartj/ehx710.

14. Draft lists of medicines based on the results of the meetings of the Commission of the Ministry of health of Russia 2019. (In Russ.) https://www.rosminzdrav.ru/ministry/61/10/stranitsa-858/proekty-perechney-lekarstvennyh-aktovpo-rezultatam-zasedaniy-komissii-minzdrava-rossii-2019-god (28 September 2018).

15. Moriarty PM, Parhofer KG, Babirak SP, et al. Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial. European heart journal. 2016;37(48):3588-95. doi:10.1093/eurheartj/ehw388.

16. Ziryanov SK, Dyakov IN. Economic expertise of alirocumab in standard lipid lowering therapy insusceptibility. Kachestvennaya Klinicheskaya Praktika. 2016;4:4-13. (In Russ.)

17. Landmesser U, Chapman MJ, Stock JK, et al. 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. European heart journal. 2017;39(14):1131-43. doi:10.1093/eurheartj/ehx549.